

Supplemental Material

Table S1. Background Characteristics

Abbreviation; ASA: aspirin; CPG: clopidogrel; PSG: prasugrel; IQR: interquartile range

¹Statistical tests performed: Wilcoxon rank-sum test for continuous variable; Fisher's exact test for sex, location and device

| Character | Item | Total (n=217) | Tailored group (n=167) | sub-group | | non-Tailored group (n=50) | P-value ¹ | |
|-----------|-----------------------|----------------------------------|---------------------------|--------------------------|-------------------------|------------------------------|----------------------|------------|
| | | | | CPG sub-group (n=140) | PSG sub-group (n=27) | | | |
| age | mean ± SD | 60.9 ± 12.3 | 61.6 ± 12.5 | 62.0 ± 12.4 | 59.3 ± 13.2 | 58.4 ± 11.4 | 0.068 | |
| | median (IQR) | 61.0 (51-70) | 63.0 (52-73) | 64.0 (53-73) | 61.0 (49-69) | 57.5 (51-67) | | |
| sex | man | 71 (32.7%) | 55 (32.9%) | 51 (36.4%) | 4 (14.8%) | 16 (32.0%) | >0.999 | |
| | woman | 146 (67.3%) | 112 (67.1%) | 89 (63.6%) | 23 (85.2%) | 34 (68.0%) | | |
| Location | Anterior circulation | ICA | 136 (62.7%) | 107 (64.1%) | 86 (61.4%) | 21 (77.8%) | 29 (58.0%) | 0.505 |
| | | ACA, Acom | 27 (12.4%) | 20 (12.0%) | 18 (12.9%) | 2 (7.4%) | 7 (14.0%) | 0.807 |
| | | MCA | 4 (1.8%) | 2 (1.2%) | 2 (1.4%) | 0 (0%) | 2 (4.0%) | 0.228 |
| | Posterior circulation | BA | 30 (13.8%) | 23 (13.8%) | 19 (13.6%) | 4 (14.8%) | 7 (14.0%) | >0.999 |
| | | VA | 21 (9.7%) | 16 (9.6%) | 16 (11.4%) | 0 | 5 (10.0%) | >0.999 |
| Device | Coil embolization (C) | 66 (30.6%) | 47 (28.3%) | 37 (26.6%) | 10 (37.0%) | 19 (38.0%) | 0.011 | |
| | coil with stenting | Coil with Stenting (S) | 106 (49.1%) | 80 (48.2%) | 68 (48.9%) | 12 (44.4%) | | 26 (52.0%) |
| | | Coil with multiple stenting (Sm) | 20 (9.3%) | 15 (9.0%) | 13 (9.4%) | 2 (7.4%) | | 5 (10.0%) |
| | Flow Diverter (FD) | 24 (11.1%) | 24 (14.5%) | 21 (15.1%) | 3 (11.1%) | 0 | | |

Table S2. DWI grading

Abbreviation; ASA: aspirin; CPG: clopidogrel; PSG: prasugrel

| The DWI grade | Total (n=217) | Tailored group (n=167) | sub-group CPG sub-group (n=140) | PSG sub-group (n=27) | Symptomatic lesion | non-Tailored group (n=50) | Symptomatic lesion |
|-------------------|---------------|------------------------|---------------------------------|----------------------|--------------------|---------------------------|--------------------|
| A (no HIA) | 44 (20%) | 35 (20%) | 33 (24%) | 2 (7%) | 1 | 9 (18%) | 0 |
| B (1-4 small HIA) | 71 (33%) | 60 (36%) | 44 (31%) | 16 (59%) | 0 | 11 (22%) | 0 |
| C (>5 small HIA) | 78 (36%) | 55 (33%) | 48 (34%) | 7 (25%) | 1 | 23 (46%) | 4 |
| D (any large HIA) | 22 (10%) | 16 (9%) | 14 (10%) | 2 (7%) | 5 | 6 (12%) | 3 |
| E (not examined) | 2 (1%) | 1 (1%) | 1 (1%) | 0 (0%) | - | 1 (2%) | - |

Figure S1. DWI grading





Figure S2. DWI grading

Figure S3. PRU cut-off in terms of TECs